Last edition
News about Global Pharma
Fabhalta from Novartis Meets Phase-III Goal in Slowing Kidney Decline in IgAN Patients
Fabhalta (iptacopan) from Novartis met its Phase III primary endpoint, slowing kidney function decline in IgA nephropathy (IgAN) patients. The first approved complement inhibitor for IgAN, Fabhalta builds on its 2024 U.S. accelerated approval, with data supporting a 2026 traditional FDA submission.
Global Pharma | 17/10/2025 | By Dineshwori
NAYA Therapeutics, a US-based clinical-stage biopharmaceutical company developing next-generation cancer therapies, has entered into a research and manufacturing partnership with China’s Alpha Nuclide, a radiopharmaceutical solutions company leading global efforts in Astatine-211 (211At) supply and CDMO services.
Global Pharma | 17/10/2025 | By Dineshwori
Graph Secures USD 3 Million Seed Funding from Bessemer for AI-Driven Drug Safety
California-based Graph AI has announced its USD 3 Million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.
Global Pharma | 17/10/2025 | By Dineshwori
Sanofi Names Montpellier Global Hub for Autoimmune Disease Research
Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.
Global Pharma | 16/10/2025 | By Dineshwori
AstraZeneca opens expanded manufacturing facility in Texas
AstraZeneca’s USD 445 million investment will support global manufacturing of Lokelma
Global Pharma | 16/10/2025 | By Dineshwori
PENTAX Medical Sells C2 CryoBalloon Technology to Merit Medical Systems
PENTAX Medical, a division of the Japanese med-tech company HOYA Group and a global leader in flexible reusable endoscopy, has signed an asset purchase agreement with the American healthcare technology company Merit Medical Systems for the sale of its C2 CryoBalloon technology.
Global Pharma | 16/10/2025 | By Dineshwori
Becton Dickinson CFO Chris DelOrefice to Step Down; Vitor Roque Appointed Interim Successor
American medical technology giant Becton Dickinson and Co. (BD) has announced that Chris DelOrefice, Executive Vice President and Chief Financial Officer, will depart the company on December 5, 2025, to pursue a new professional opportunity.
Global Pharma | 16/10/2025 | By Dineshwori
Viatris Acquires Aculys Pharma, Secures Exclusive Rights to Pitolisant and Spydia in Japan
Viatris has completed the acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercialising innovative treatments for neurological conditions.
Global Pharma | 16/10/2025 | By Dineshwori
China Approves GSK's Shingrix for Shingles Prevention
The China National Medical Products Administration (NMPA) has approved GSK’s Shingrix (Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
Global Pharma | 15/10/2025 | By Dineshwori
EY Acquires Aqurance to Boost Lifesciences Transformation on Veeva
The acquisition of Aqurance aims to strengthen the EY organisation’s Veeva Centers of Excellence, expanding clinical, regulatory and commercial services capabilities for global pharma and biotech.
Global Pharma | 15/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy